CGON (CG Oncology) Research & Development: $132.90 Mil (TTM As of Mar. 2026)


CGON CG Oncology Inc CGON
12 GF Score
Price $71.96
! 6 Warning Signs
View Full Analysis

What is CG Oncology Research & Development?

CG Oncology CGON -1.22% 12 Research & Development is $132.90 Mil as of Mar. 2026. GuruFocus rates CGON with a GF Score™ of 12/100. The stock has 6 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. CG Oncology's Research & Development for the three months ended in Mar. 2026 was $43.73 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $132.90 Mil.

CG Oncology  (NAS:CGON) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

CG Oncology Research & Development Related Terms

CG Oncology Research & Development Historical Data

* Premium members only.

The historical data trend for CG Oncology's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CG Oncology Research & Development Chart

CG Oncology Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
18.32 29.03 45.75 82.10 116.64

CG Oncology Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.47 31.33 27.88 29.96 43.73
CGON
12GF Score
CG Oncology Inc CGON
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CG Oncology Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $132.90 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $132.90 Mil mean?
CG Oncology (CGON) has a Research & Development of $132.90 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on CG Oncology and its competitors.
Is CG Oncology's Research & Development too high?
CG Oncology's current Research & Development is $132.90 Mil. Overall, CG Oncology has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does CG Oncology's Research & Development compare to CRSP and XENE?
CG Oncology's Research & Development of $132.90 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on CG Oncology and its competitors. CG Oncology's current Research & Development is $132.90 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CG Oncology stock overvalued right now?
CG Oncology (CGON) has a current Research & Development of $132.90 Mil. The current Research & Development is $132.90 Mil. CG Oncology's overall GF Score™ is 12/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For CG Oncology (CGON), the current Research & Development is $132.90 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CG Oncology Business Description

Address 400 Spectrum Center Drive, Suite 2040, Irvine, CA, USA, 92618
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
12GF Score

Get the complete analysis for CGON

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$71.96
Price